Williams Jones Wealth Management LLC. Sells 14,677 Shares of Genmab A/S (NASDAQ:GMAB)

Williams Jones Wealth Management LLC. lessened its holdings in Genmab A/S (NASDAQ:GMABGet Rating) by 5.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 255,457 shares of the company’s stock after selling 14,677 shares during the quarter. Williams Jones Wealth Management LLC.’s holdings in Genmab A/S were worth $9,242,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the business. BlackRock Inc. boosted its stake in Genmab A/S by 1.6% in the 1st quarter. BlackRock Inc. now owns 5,494,689 shares of the company’s stock valued at $198,799,000 after buying an additional 86,571 shares in the last quarter. Stifel Financial Corp grew its holdings in shares of Genmab A/S by 1.1% in the 4th quarter. Stifel Financial Corp now owns 1,209,423 shares of the company’s stock worth $47,844,000 after purchasing an additional 12,587 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of Genmab A/S by 1.3% during the 1st quarter. Renaissance Technologies LLC now owns 1,088,500 shares of the company’s stock worth $39,382,000 after purchasing an additional 14,100 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in Genmab A/S by 63.9% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 869,221 shares of the company’s stock valued at $31,448,000 after purchasing an additional 338,902 shares during the last quarter. Finally, American Century Companies Inc. boosted its position in Genmab A/S by 956.7% in the first quarter. American Century Companies Inc. now owns 420,839 shares of the company’s stock valued at $15,226,000 after buying an additional 381,013 shares in the last quarter. Institutional investors and hedge funds own 5.51% of the company’s stock.

Genmab A/S Stock Down 0.1 %

NASDAQ:GMAB opened at $37.44 on Friday. Genmab A/S has a 12-month low of $26.19 and a 12-month high of $47.28. The stock’s fifty day simple moving average is $35.41 and its 200-day simple moving average is $33.78. The firm has a market capitalization of $24.64 billion, a P/E ratio of 41.60, a P/E/G ratio of 1.43 and a beta of 0.85.

Genmab A/S (NASDAQ:GMABGet Rating) last issued its earnings results on Wednesday, August 10th. The company reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.21 by $0.20. The firm had revenue of $452.86 million for the quarter, compared to analysts’ expectations of $435.40 million. Genmab A/S had a return on equity of 17.12% and a net margin of 38.42%. As a group, equities research analysts expect that Genmab A/S will post 0.99 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. BMO Capital Markets started coverage on Genmab A/S in a report on Thursday, June 23rd. They issued a “market perform” rating and a $34.73 target price on the stock. HC Wainwright raised their target price on Genmab A/S from $49.00 to $51.00 and gave the company a “buy” rating in a research note on Monday, August 22nd. SVB Leerink upped their price target on shares of Genmab A/S from $30.00 to $31.00 and gave the stock a “market perform” rating in a research report on Thursday, August 11th. Morgan Stanley raised their price objective on shares of Genmab A/S from $29.00 to $31.00 and gave the company an “underweight” rating in a research report on Monday, August 15th. Finally, TheStreet raised shares of Genmab A/S from a “c+” rating to a “b” rating in a research note on Wednesday, August 31st. One analyst has rated the stock with a sell rating, eight have issued a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, Genmab A/S has a consensus rating of “Hold” and an average price target of $476.25.

Genmab A/S Profile

(Get Rating)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Read More

Want to see what other hedge funds are holding GMAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genmab A/S (NASDAQ:GMABGet Rating).

Institutional Ownership by Quarter for Genmab A/S (NASDAQ:GMAB)

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.